PCSK9 Inhibitors: Heralding A New Era In Dyslipidemia Management

Abstract

Dyslipidemia is a well known risk factor for cardiovascular disease. Till now statins were the sheet anchor of therapy for dyslipidemia. But there are a few patients who are intolerant to statins and some who develop cardiovascular disease in spite of maximally tolerated dose of statins. Still there are some others like those with familial hypercholesterolemia who do not achieve adequate reduction of cholesterol levels with statins alone or in combination with ezetimibe. Now we have a new group of medications - proprotein convertase subtilsin-kexin type 9 (PCSK9) inhibitors, to cater to these group of patients.